Course Curriculum

    1. Disclosure

    2. Why We Are Here

    3. Federal Compound Laws

    4. Transition to Biologics

    5. What is a Biologic

    6. Biologic Products

    7. What is a Peptide

    8. BPCI Impact to Compounding

    9. SECTION 503A: Bulk Substance Requirements

    10. Bulk Substance List

    11. Interim Policy on Compounding Drugs Using Bulk Drug Substances

    12. Current Status of Commonly Used Peptide

About this course

  • $499.00
  • 12 lessons

Meet Our Expert

Jason McClaren, J.D.

Attorney

Currently, Jason works as Vice President and General Counsel at National Financial Companies, LLC which is a merchant banking firm founded in 1991 to pursue high growth investment opportunities with specific interests in the healthcare, pharmacy, financial services, manufacturing, and consumer product sectors. Previously, Jason worked as litigation associate at Frier & Levitt, LLC. Also, Jason worked as a litigation associate at the JTB Law Group, LLC where he was responsible for managing and litigating an active personal injury case load. Additionally, Jason worked as a senior medical reviewer at Bayer Pharmaceuticals where he reviewed, analyzed and extracted information from medical records for cases currently undergoing litigation. Further, Jason was a contracts attorney for Partners HealthCare System, Inc., where he worked on industry sponsored clinical research agreements. Jason also volunteered as an attorney for Health Law Advocates where he represented low income clients on matters relating to access and payment of medical services. Jason earned his J.D. from Suffolk University School of Law and his Pharm.D. from the Massachusetts College of Pharmacy and Health Sciences. Specialties: health care law, FDA regulatory law, contract drafting and negotiation, drug safety, discovery document review